Algorhythm Holdings Secures $10.355M in Highly Dilutive "Death Spiral" Financing

summarizeSummary

Algorhythm Holdings, a micro-cap company, secured $10.355 million in a fourth pre-paid purchase agreement with Streeterville Capital, receiving $9.5 million in gross proceeds, but under terms that are highly dilutive and indicative of financial distress.

check_boxKey Events · Financing and Capital Events · RIME

• Secured $10.355M Pre-Paid Purchase

  Algorhythm Holdings entered into its fourth pre-paid purchase agreement with Streeterville Capital for a principal amount of $10,355,000, receiving $9.5 million in gross proceeds.

• Highly Dilutive Terms

  The financing includes an $855,000 original issue discount and a variable conversion price set at 90% of the lowest daily VWAP over 10 trading days, with a $0.30 floor, which is highly unfavorable for existing shareholders.

• Significant Capital Infusion for Micro-Cap

  For a company with a market cap of approximately $5 million, the $9.5 million gross proceeds (initially $5.52 million net after fees and DACA deposit) represents a substantial capital raise, critical for short-term operations.

• Secured by Cash and Subsidiary Assets

  $3.5 million of the proceeds are held in a secured deposit account controlled by the investor, and the purchase is guaranteed by a wholly-owned subsidiary, RIME Holdings, LLC, and secured by its assets.

auto_awesomeAnalysis · RIME · Technology

This 8-K details a critical financing event for Algorhythm Holdings, securing $10.355 million in principal through a "Secured Pre-Paid Purchase #4" with Streeterville Capital. While the company receives $9.5 million in gross proceeds (initially $5.52 million net after fees and DACA deposit), the terms are extremely unfavorable and highly dilutive for existing shareholders. The variable conversion price, set at 90% of the lowest daily VWAP over a 10-day period with a $0.30 floor, is characteristic of "death spiral" financing. This structure incentivizes the investor to convert at lower prices, potentially leading to significant downward pressure on the stock as more shares are issued and sold. The high original issue discount, 9% interest rate, and restrictive covenants further highlight the company's weak bargaining position and financial distress. While the capital infusion provides a short-term lifeline for this micro-cap company, the long-term implications for shareholder value are severely negative due to the substantial dilution and the mechanism of the financing.